海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688302 海创药业

已收盘 04-26 15:00:01

{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":27.9,"timestamp":1714114801000,"preClose":27.39,"halted":0,"volume":577829,"delay":0,"floatShares":72724500,"shares":99015600,"eps":-2.8966,"marketStatus":"已收盘","marketStatusCode":5,"change":0.51,"latestTime":"04-26 15:00:01","open":27.52,"high":27.98,"low":26.88,"amount":15984100,"amplitude":0.0402,"askPrice":27.91,"askSize":16,"bidPrice":27.9,"bidSize":235,"shortable":0,"etf":0,"ttmEps":-2.8966,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714354200000},"adr":0,"adjPreClose":27.39,"symbolType":"stock_kcb","openAndCloseTimeList":[[1714095000000,1714102200000],[1714107600000,1714114800000]],"highLimit":30.13,"lowLimit":24.65,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"pbRate":2.02,"roa":"--","roe":"--","epsLYR":-2.97,"committee":0.557377,"marketValue":2763000000,"floatMarketCap":2029000000,"peRate":-9.631982,"changeRate":0.0186,"turnoverRate":0.0079,"status":0,"afterMarket":{"amount":0,"volume":0,"close":27.9,"buyVolume":0,"sellVolume":0,"time":1714116839505,"indexStatus":"已收盘 04-26 15:30:00","preClose":27.39}},"requestUrl":"/m/hq/s/688302/wiki","defaultTab":"wiki","newsList":[{"id":"2430249418","title":"海创药业(688302.SH)发布一季度业绩，净亏损4721万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430249418","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430249418?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:12","pubTimestamp":1714119125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)披露2024年第一季度报告，报告期公司实现营收0元;归母净利润亏损4721万元;扣非净利润亏损5272万元。基本每股收益-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616140987b29e27&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616140987b29e27&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430424946","title":"海创药业：一季度营收0元，净亏4721.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430424946","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2430424946?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:56","pubTimestamp":1714118193,"startTime":"0","endTime":"0","summary":"海创药业4月26日公告，公司一季度营业收入0元；净亏4721.48万元；基本每股收益-0.48元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261556337a560579&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261556337a560579&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430249467","title":"海创药业：一季度净利润亏损4721.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430249467","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430249467?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:56","pubTimestamp":1714118160,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，海创药业(688302)4月26日晚间披露一季报，2024年第一季度营业收入0元，净利润亏损4721.48万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261557178b562ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261557178b562ddd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150737","title":"4月23日海创药业-U涨5.84%，鹏华创新增长一年持有期混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150737","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429150737?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:26","pubTimestamp":1713860803,"startTime":"0","endTime":"0","summary":"证券之星消息，4月23日海创药业-U涨5.84%，收盘报26.47元，换手率1.7%，成交量1.24万手，成交额3202.44万元。重仓海创药业-U的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华创新增长一年持有期混合A。该公募基金现任基金经理为金笑非。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029739.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150735","title":"海创药业-U涨5.84%，西南证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150735","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429150735?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:26","pubTimestamp":1713860797,"startTime":"0","endTime":"0","summary":"今日海创药业-U涨5.84%，收盘报26.47元。2024年4月15日，西南证券研究员杜向阳发布了对海创药业的研报《2023年报点评：氘恩扎卢胺有望2024年底获批上市》，该研报对海创药业给出“买入”评级。研报中预计公司2024-2026年实现营业收入分别约为0.1、1.6、3.8亿元。考虑海创药业研发实力强劲，氘代和PROTAC技术平台实力出众，首款创新药德恩鲁胺NDA已获受理，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为财通证券的华挺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300029729.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429083130","title":"海创药业-U大幅上涨 生物医药行业人才需求增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2429083130","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2429083130?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:42","pubTimestamp":1713850976,"startTime":"0","endTime":"0","summary":"04月23日，海创药业-U股价大幅上涨，截至13点42分，海创药业-U上涨5.16%，报26.30元/股，成交1791万元，换手率0.97%。该团体标准由上海现代服务业联合会与中国进出口银行上海分行联合发起，复旦大学药学院、上海现代服务业标准创新发展中心等生物医药产业链上的相关机构共同参与制定。北向资金方面，海创药业-U04月22日获得北向资金增持1.83万股，截至04月22日，北向资金当前共持有海创药业-U15.51万股，市值407万元，持股占流通股比为0.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313435379228339&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313435379228339&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428393027","title":"海创药业-U涨7.29%，西南证券二日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2428393027","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2428393027?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:21","pubTimestamp":1713342086,"startTime":"0","endTime":"0","summary":"今日海创药业-U涨7.29%，收盘报26.35元。2024年4月15日，西南证券研究员杜向阳发布了对海创药业的研报《2023年报点评：氘恩扎卢胺有望2024年底获批上市》，该研报对海创药业给出“买入”评级。考虑海创药业研发实力强劲，氘代和PROTAC技术平台实力出众，首款创新药德恩鲁胺NDA已获受理，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为财通证券的华挺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716241687880362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716241687880362&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428382642","title":"海创药业去年亏损2.94亿元 原始股东频繁减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428382642","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2428382642?lang=zh_cn&edition=full","pubTime":"2024-04-17 00:27","pubTimestamp":1713284820,"startTime":"0","endTime":"0","summary":"　　近日，凭借第五套标准登陆科创板的海创药业交出了其上市后的第二份年度“成绩单”。年报显示，2023年海创药业尚无药品获得商业销售批准，无营业收入，归属于上市公司股东的净利润为-2.94亿元，扣非净利润为-3.25亿元。　　《经济参考报》记者注意到，这已是海创药业连续第六年出现亏损，其中上市两年时间亏损金额达5.96亿元。值得一提的是，在业绩与股价双重压力之下，海创药业多名原始股东也在频繁抛售公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-04-17/doc-inasaeuq9241009.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-04-17/doc-inasaeuq9241009.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2427584619","title":"4月16日海创药业-U跌8.01%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427584619","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427584619?lang=zh_cn&edition=full","pubTime":"2024-04-16 17:43","pubTimestamp":1713260613,"startTime":"0","endTime":"0","summary":"证券之星消息，4月16日海创药业-U跌8.01%创60日新低，收盘报24.56元，换手率2.21%，成交量1.6万手，成交额4017.63万元。该股为创新药、医药、新冠药物概念热股。重仓海创药业-U的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2023基金年报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为鹏华医药科技股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161747048b29ea8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161747048b29ea8d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427686485","title":"海创药业-U创新低 2023年度报告显示无营收亏损增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2427686485","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2427686485?lang=zh_cn&edition=full","pubTime":"2024-04-16 09:42","pubTimestamp":1713231726,"startTime":"0","endTime":"0","summary":"04月16日，海创药业-U股价大幅下跌，截至09点42分，海创药业-U下跌5.02%，报25.36元/股，创历史新低，成交646万元，换手率0.35%。海创药业主要从事癌症、代谢性疾病等治疗领域的创新药物研发，2022年4月在科创板上市，募集资金净额为9.95亿元。2023年，海创药业研发费用2.48亿元，与2022年基本持平。截至本报告披露日，海创药业拥有7项创新药物的在研项目。资金动向截止发稿，海创药业-U获得主力净流出156万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161039487920ca00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161039487920ca00&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427076676","title":"海创药业(688302)：氘恩扎卢胺有望2024年底获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2427076676","media":"西南证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2427076676?lang=zh_cn&edition=full","pubTime":"2024-04-15 19:08","pubTimestamp":1713179303,"startTime":"0","endTime":"0","summary":"氘恩扎鲁胺软胶囊NDA获NMPA受理，有望成为国内获批mCRPC二线治疗的首款AR抑制剂。2023 年初至今，公司共获得了5项临床试验批准，其中中国3项，美国2项。HP501 用于治疗痛风相关的高尿酸血症的Ⅱ期临床于2023 年12 月获FDA 批准，HP501 中国联合用药的IND申请于2024年4月获NMPA批准。HP537片中国IND于2024年2 月获NMPA 批准。考虑海创药业研发实力强劲，氘代和PROTAC 技术平台实力出众，首款创新药德恩鲁胺NDA 已获受理，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151908278b25c1f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151908278b25c1f9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427602161","title":"海创药业2023年亏损2.94亿 亏损减少 董事长陈元伟薪酬317.74万","url":"https://stock-news.laohu8.com/highlight/detail?id=2427602161","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2427602161?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:46","pubTimestamp":1713170804,"startTime":"0","endTime":"0","summary":"挖贝网4月15日，海创药业 近日发布2023年年度报告，归属于上市公司股东的净利润-294,158,414.14元，同比下滑93.05%。本报告期内公司归属于母公司所有者的净利润为-29,415.84万元，亏损同比减少2.44%；归属于母公司所有者的扣除非经常性损益的净利润为-32,502.96万元，亏损同比减少4.55%。报告期末总资产149,156.51万元,较期初减少14.03%；归属于母公司的所有者权益136,709.03万元，较期初减少13.77%。公告显示，报告期内董事、监事、高级管理人员报酬合计1,613.88万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151651158b254afa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151651158b254afa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427048299","title":"海创药业-U大幅下跌 创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2427048299","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2427048299?lang=zh_cn&edition=full","pubTime":"2024-04-15 13:28","pubTimestamp":1713158885,"startTime":"0","endTime":"0","summary":"04月15日，海创药业-U股价大幅下跌，截至13点28分，海创药业-U下跌5.01%，报26.36元/股，创历史新低，成交2588万元，换手率1.29%，振幅8.36%。资金动向截止发稿，海创药业-U获得主力净流入233万元，其中超大单流入164万元，大单流入68万元。北向资金方面，海创药业-U04月12日获得北向资金增持5.72万股，截至04月12日，北向资金当前共持有海创药业-U23.22万股，市值612万元，持股占流通股比为0.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151329087a52b8ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404151329087a52b8ff&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427301179","title":"海创药业去年研发费用达2.48亿 尚无产品上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2427301179","media":"新京报","top":-1,"share":"https://www.laohu8.com/m/news/2427301179?lang=zh_cn&edition=full","pubTime":"2024-04-15 11:46","pubTimestamp":1713152796,"startTime":"0","endTime":"0","summary":"海创药业主要从事癌症、代谢性疾病等治疗领域的创新药物研发，2022年4月在科创板上市，募集资金净额为9.95亿元。截至2023年12月31日，尚未盈利且存在累计未弥补亏损。2023年，海创药业研发费用2.48亿元，与2022年基本持平。截至本报告披露日，海创药业拥有7项创新药物的在研项目。新药上市申请已获得国家药品监督管理局药品审评中心受理，尚未开展商业化生产销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415114737877d82a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415114737877d82a8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427042546","title":"“0收入”叠加股价破发，IPO前投资海创药业的机构们亏惨了 | 看财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2427042546","media":"钛媒体","top":-1,"share":"https://www.laohu8.com/m/news/2427042546?lang=zh_cn&edition=full","pubTime":"2024-04-15 00:03","pubTimestamp":1713110585,"startTime":"0","endTime":"0","summary":"图片系AI生成无商业化产品、无营收、年年巨亏、股价来回破发、IPO前的投资机构们浮亏严重，这是海创药业-U面临的窘境。4月13日，登陆科创板两周年的海创药业披露上市以来的第二份年报，2023年营业收入为0元，净利润亏损2.94亿元。换言之，海创药业过去四年合计亏损13.92亿元，上市两年亏损近6亿元。按照海创药业在招股书披露的计划，氘恩扎鲁胺软胶囊预计于2024年年底上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415000313877b2efa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415000313877b2efa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427717437","title":"海创药业(688302)3月31日股东户数0.36万户，较上期增加21.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427717437","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2427717437?lang=zh_cn&edition=full","pubTime":"2024-04-13 17:02","pubTimestamp":1712998938,"startTime":"0","endTime":"0","summary":"证券之星消息，近日海创药业披露，截至2024年3月31日公司股东户数为3601.0户，较12月31日增加626.0户，增幅为21.04%。在化学制药行业个股中，海创药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.39万户。从股价来看，2023年12月31日至2024年3月31日，海创药业区间跌幅为40.81%，在此期间股东户数增加626.0户，增幅为21.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131704118b1c698e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131704118b1c698e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427715790","title":"海创药业：2023年全年净亏损2.94亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427715790","media":"新京报网","top":-1,"share":"https://www.laohu8.com/m/news/2427715790?lang=zh_cn&edition=full","pubTime":"2024-04-13 14:19","pubTimestamp":1712989140,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯 4月13日，海创药业发布2023年全年业绩报告。其中归属于母公司所有者的净利润为-29415.84万元，亏损同比减少2.44%。据业绩报告显示，公司归属于母公司所有者的净利润为-29415.84万元，亏损同比减少2.44%；归属于母公司所有者的扣除非经常性损益的净利润为-32502.96万元，亏损同比减少4.55%。报告期末总资产为149156.51万元，较期初减少14.03%；归属于母公司的所有者权益为136709.03万元，较期初减少13.77%。编辑 覃澈校对 赵琳","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131419587a528179&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404131419587a528179&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427791057","title":"海创药业(688302.SH)发2023年度业绩，未实现营收，净亏损2.94亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2427791057","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2427791057?lang=zh_cn&edition=full","pubTime":"2024-04-13 11:06","pubTimestamp":1712977560,"startTime":"0","endTime":"0","summary":"海创药业发布2023年年度报告，报告期内公司未实现营业收入;归属于上市公司股东的净亏损2.94亿元，同比亏损收窄;归属于上市公司股东扣除非经常性损益净亏损3.25亿元，同比亏损收窄;基本每股亏损2.97元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-13/doc-inarrzpw7082091.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-13/doc-inarrzpw7082091.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426673461","title":"海创药业将于5月10日召开股东大会，审议公司2023年度财务决算报告等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2426673461","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426673461?lang=zh_cn&edition=full","pubTime":"2024-04-12 23:36","pubTimestamp":1712936203,"startTime":"0","endTime":"0","summary":"金融界4月12日消息，海创药业发布公告，将于2024年5月10日召开年度股东大会，网络投票同日进行。股权登记日为5月7日，当日收市后持有海创药业股票的投资者可以参与投票。会议地点：四川省成都市高新区科园南路5号蓉药大厦1栋4层公司会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122337488b17e8b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404122337488b17e8b5&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":0.0699},{"period":"1month","weight":-0.2035},{"period":"3month","weight":-0.3173},{"period":"6month","weight":-0.348},{"period":"1year","weight":-0.5994},{"period":"ytd","weight":-0.474}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"20195股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":0.0071},{"period":"3month","weight":0.049},{"period":"6month","weight":0.0116},{"period":"1year","weight":-0.0647},{"period":"ytd","weight":0.0262}],"survey":"　　海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台，以开发具有重大临床需求的Best-in-class（同类最佳）、First-in-class（国际首创）药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局，重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台，形成了较强的研发优势和丰富的技术储备。","serverTime":1714120523176,"listedPrice":42.92,"stockholders":"3601人(较上一季度增加21.04%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}